We are live on ! Find out more
TTNP

Titan Pharmaceuticals

Delisted

TTNP was delisted on the 1st of October, 2025.

Fund managers haven’t disclosed any holdings of TTNP yet.

TTNP Hedge Fund Activity: Q1 2026 in Review

6 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q1 2026, worth a combined $130 — down 16% from $154 a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new TTNP positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Bogart Wealth LLC, opening a new position worth an estimated $1.

  • 6 institutional investors held Titan Pharmaceuticals (TTNP) as of Q1 2026, up from 4 in Q4 2025.
  • Funds reported $130 of Titan Pharmaceuticals stock for Q1 2026, down 16% quarter-over-quarter.
  • 2 funds opened new Titan Pharmaceuticals positions in Q1 2026 and 0 closed out, a net change of +2 holders.
  • The largest Titan Pharmaceuticals buyer in Q1 2026 was Bogart Wealth LLC, an estimated $1 added.

Based on aggregated 13F filings for Q1 2026.